22 Oct 2015 14:22
Immunodiagnostic Systems Holdings plc
Board Appointment
22 October 2015
Immunodiagnostic Systems Holdings plc ("IDS" or "the Company" or "the Group"), a leading solution provider to the clinical laboratory diagnostic market, is pleased to announce that Paul James Martin, aged 38, will join the Board of IDS as CFO from 4 January 2016.
Paul Martin is a chartered accountant who started his career at Arthur Andersen. In 2006 he was hired as a financial controller at tech start-up SpinVox before becoming Vice President of Finance at ACISION in 2008. Since 2010 he has been working at Volex plc firstly as Finance Director of the Asia division where he led a finance team of approximately 70 before being promoted to CFO of the company's Power Division in 2013.
Burkhard Wittek, Non-Executive Chairman of IDS said: "Paul has extensive experience managing the finances of a wide range of businesses across the globe. He also adds significant project experience in increasing operating efficiencies. We welcome him to the board of IDS."
The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies:
Current Directorships and Partnerships:
N/A
Previous Directorships and Partnerships in last five years:
Volex PTE LimitedVolex (Asia) PTE LimitedVolex Cable Assemblies Sdn BhdPT Volex IndonesiaPT Volex Cable AssemblyVolex (Thailand) Co LimitedVolex Cable Assembly (Vietnam) Co LimitedVolex Cables (HK) LimitedVolex Cables Assembly (Shenzhen) Co LimitedVolex Cables Assembly (Zhongshan) Co LimitedVolex Interconnect Systems (Suzhou) CoVolex Japan KKVolex (Taiwan) Co LtdVolex Cable Assemblies (Phils) IncVolex International Korea LLC
There are no other disclosures required in relation to Rule 17 or paragraph (g) of Schedule 2 of the AIM Rules for Companies.
For further information:
Immunodiagnostic Systems Holdings plc
Tel : +44 (0)191 519 0660
Patricio Lacalle, Chief Executive Officer
Peel Hunt LLP
Tel : +44 (0)207 418 8900
James Steel
Oliver Jackson
About Immunodiagnostic Systems Holdings PLC:
The Group's vision is to be a leading solution provider to the clinical laboratory diagnostic market. IDS's strategy is focused on developing, internally and through partnership, its automated assay menu for its proprietary automated immunoassay analyser, the IDS-iSYS system. Internally the Group is focused on developing an endocrinology excellence menu and externally IDS works with partners to develop assay panels in complementary indication fields. The Group sells its products primarily in the clinical laboratory market across a range of customers from reference laboratories to physician office laboratories. IDS has field sales forces in certain European countries, including France and Germany, the United States and Brazil and works with distributors in other markets including China, Italy and Spain.